ChromaDex launches NIAGEN nicotinamide riboside

ChromaDex launches NIAGEN nicotinamide riboside

Could this ingredient be the next-gen niacin?

ChromaDex Corp. (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the launch of NIAGEN™, its novel, patented, branded nicotinamide riboside.

ChromaDex's NIAGEN has the potential to be a next-generation niacin (vitamin B3) and become part of the portfolio of B vitamin ingredients that are included in products serving multibillion-dollar markets such as multivitamins, nutraceuticals, weight loss, energy drinks, sports nutrition, meal replacements, infant formula, food and beverage products.

NIAGEN may have tremendous appeal to the approximately 150 million Americans who are obese or overweight, as well as the 75 million aging baby boomers in the U.S.—both of which are actively seeking new dietary supplement solutions for obesity or healthy aging. These large segments of the U.S. population continue to fuel the growing multi-billion dollar dietary supplement markets.

NIAGEN is the first and only commercially available brand of NR. Over the past two years, ChromaDex has built a significant patent portfolio pertaining to NR by separately acquiring patent rights from Cornell University, Dartmouth College and Washington University. ChromaDex believes its patent rights create a significant and meaningful barrier to entry for would-be competitors in the NR market.

Frank Jaksch, founder and CEO, states "By solving the immense challenge of producing NR on a commercially viable scale, we have achieved the first step in unlocking the potential of this new vitamin. The formal launch of NIAGEN, our branded nicotinamide riboside, will immediately allow dietary supplement, and food & beverage companies to include NIAGEN in product formulations.

Jaksch continues, "We are in the final stages of completing the design of our first human clinical study for NIAGEN. Additionally, we continue to collaborate with several universities and research institutes who have ongoing research activities designed to validate the tremendous health benefits of NR as well as create a strong commercial platform of health claims."


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.